KiOmed Pharma Clinches $18M Funding to Revolutionize Medical Devices with Chitosan Innovation

KiOmed Pharma is excited to announce that it has successfully raised $18,000,000 in its latest funding round, marking a significant milestone for the company as it seeks to expand its groundbreaking work in medical device innovation. Originating as a spinout from KitoZyme, KiOmed Pharma capitalizes on its rich history of innovation and deep expertise in exclusive natural chitosan chemistry to develop a unique pipeline of products addressing critical healthcare challenges. This substantial investment will empower the company to accelerate research and development and to bring transformative solutions to patients experiencing unmet medical needs, specifically targeting high impact pathologies such as OsteoArthritis, the debilitating conditions associated with skin aging, and various ophthalmologic issues. By integrating cutting-edge science with a commitment to improving patient outcomes, the new funds will support the advancement of early-stage as well as later-stage device candidates, refine clinical studies, and bolster manufacturing capabilities to meet anticipated market demand. The investment is a strong vote of confidence in KiOmed Pharma’s strategic vision and its potential to make a significant impact on major social burdens and chronic conditions. Backed by this financial boost, the company is poised to navigate the complexities of the healthcare market, cultivating partnerships with key stakeholders and leveraging its proprietary technology to deliver innovative, effective, and safe solutions that enhance quality of life. As KiOmed Pharma embarks on this exciting phase of growth, it reaffirms its commitment to creating value for patients, healthcare providers, and investors alike, promising a future of continuous innovation and improved health outcomes worldwide.